We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma has reached a major milestone in its development in January 2025, with positive topline results from its Phase 3 clinical trial evaluating its microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Enhancing Survival Through Innovative Immune Modulation
We are a late-stage clinical company developing microbiome therapies to modulate the immune system and improve cancer survival.
See News
Corporate profile
Press Releases
June 24, 2025: MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting Lyon, France,…
June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
June 13, 2025: MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
Media Coverage
June 6, 2025: Eric Soyer, directeur financier Maat Pharma : “demande d’autorisation de mise sur le marché” – Lyon Décideurs (French Only)
June 6, 2025: Biothérapie : le lyonnais MaaT Pharma franchit un cap avec son traitement à base de microbiote – La Tribune (French Only)
May 15, 2025: MaaT Pharma : Présentation investisseurs, Stratégie et Perspectives 2025 – La Bourse et La Vie (French Only)
Posters
MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe
MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial
